Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.


Related Content

Alexion Gets Second Priority Review Voucher With Approval Of Rare Enzyme Disorder Drug
Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval
Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued
Keeping Track: FDA Approves Two Novel Orphan Drugs; Breakthrough Applications Keep Agency Busy
PhRMA Awards Celebrate Breakthroughs – And Get Warning On Prices
When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts